• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay Kits
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • MAPK8 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • PKR Assay Kits
      • TBK1 Assay Kits
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • ADK Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • MAPK8 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • PKR Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Enhancing Checkpoint Blockade Immunotherapy: Sensitizing Tumors with HSP90 Inhibitors

by Bellbrook Labs / Wednesday, 02 May 2018 / Published in Emerging Targets, HTS Assays, Success Stories
HSP90 Inhibitor Immunotherapy

Checkpoint blockade is turning heads in the oncology community. This form of immunotherapy, which uses anti-PD-1 or anti-CTLA-4 antibodies to coax the immune system into recognizing and attacking cancer cells, has been a game-changer — but only for some patients. Types of cancer for which checkpoint blockade currently cannot presently be used include gastrointestinal tumors (which affect about 4,000 to 6,000 people per year in the U.S.¹), melanoma (more than 91,000 cases annually in the U.S.²), and non-small cell lung cancer (approximately 178,000 cases annually in the U.S.³), among others.

Tantalizing evidence from recent in vitro and animal studies suggest a strategy for turning “cold,” or non-responsive, tumors into “hot” tumors that are susceptible to checkpoint blockade therapy.4

To turn up the heat, researchers are returning to a target that had previously caused the pharmaceutical industry some disappointment in cancer monotherapy approaches: heat shock protein (HSP) 90, a molecular chaperone that shepherds the maturation, folding, and functional stability of a wide array of cellular proteins referred to as HSP90 client proteins.4,5

HSP90 appears to have paradoxical roles in oncology and immunology, with interesting implications for immunotherapy.  During tumorigenesis, many HSP90 client proteins appear to drive processes necessary for oncogenesis such as immortality, altered and accelerated metabolism, genomic instability, and dissemination.5 In the frenzied cellular rush of malignant progression, these HSP90 client proteins are often expressed in mutant, amplified, or translocated forms that are inherently labile, requiring HSP90 for stability.5 As a result, HSP90 is expressed highly in tumor tissues, although preclinical and early-stage clinical trials of various HSP90 inhibitors as single-agent therapies had given mixed results.4

Interestingly, although there has been some concern from in vitro studies that inhibition of HSP90 could hamper events necessary for immunotherapy (such as delivery of antigenic peptides to the surface of cancer cells, direct tumor recognition by CD4+ T cells, and antigen cross-presentation and priming), subsequent data suggest that the role of HSP90 in modulating tumor immune responses is far more nuanced.5 As it turns out, inhibiting HSP90 could potentially provide a way to overcome challenges that currently limit the effectiveness of immunotherapy — for example, by driving elevated MHC I expression in combination with paradoxically enhanced antigen expression, resulting in increased T-cell recognition of tumors.5

The theory that HSP90 inhibition could facilitate anti-tumor immunity is supported by in vitro data using a sarcoma model expressing HSP90 client protein EphA2.6 And one research team has reported preclinical evidence of improved outcomes in two mPD-L1–expressing, syngeneic mouse tumor models by administering a combination of HSP90 ganetespib with anti–PD-L1 antibody treatment.5 Further study is needed, particularly in light of toxicity issues with some first-generation HSP90 inhibitors, but the possibility that checkpoint blockade could benefit more patients – or even be made more effective for currently indicated patient populations – provides hope.

Finding HSP90 Inhibitors

The practical application of such combination therapies may require novel HSP90 inhibitors as well as precise evaluation of known HSP90 inhibitors for specific activities critical to anti-tumor immunity. Toward that end, sensitive and high throughput assays are key to increasing the pace of investigation. The Transcreener® ADP ATPase Assay Kit from BellBrook Laboratories is a one-step assay that allows direct detection of ADP with three fluorescent readouts. This assay has been proven to detect ATPase activity of yeast and human HSP90 protein7 and for characterization of the HSP90 small molecular inhibitor CPUY201112.8

The cost of checkpoint blockade immunotherapy has been met with concern about the ability of expanding access to this treatment.9 Could combination therapy with sensitizing agents such as HSP90 inhibitors provide a path toward safeguarding the effectiveness of immunotherapy, as well as expanding its applicability for currently recalcitrant types of cancer? Further investigation is needed, but it seems likely that robust, high throughput screening assays will play a role in answering these questions.

-Robyn M. Perrin, PhD

Learn More About the ATPase Assay

[1] American Cancer Society, https://www.cancer.org/cancer/gastrointestinal-stromal-tumor/about/key-statistics.html

[2] American Society for Clinical Oncology, https://www.cancer.net/cancer-types/melanoma/statistics

[3] American Society for Clinical Oncology, https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics

[4] Glaser V. 2018. Supplement: HSP90 Inhibition Turns Up the Heat on Tumors. Gen Engin Biotech News. 38(7). https://www.genengnews.com/gen-articles/supplement-hsp90-inhibition-turns-up-the-heat-on-tumors/6293

[5] Proia DA, Kaufmann GF. 2015. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy. Cancer Immunol Res. 3(6):583-9.

[6] Rao A, Taylor JL, Chi-Sabins N, Kawabe M, Gooding WE, Storkus WJ. 2012. Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic t cells. Cancer Res. 72:3196–206.

[7] Rowlands M, McAndrew C, Prodromou C, Pearl L, Kalusa A, Jones K, Workman P, Aherne W. 2010. Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using the TranscreenerTM ADP assay kit. J Biomol Screen. 15(3):279-86. https://www.ncbi.nlm.nih.gov/pubmed/20147598

[8] Xu XL, Bao QC, Jia JM, Liu F, Guo XK, Zhang MY, Wei JL, Lu MC, Xu LL, Zhang XJ, You QD, Sun HP. 2018. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells. Sci Rep. doi:10.1038/srep19004 https://www.nature.com/articles/srep19004

[9] Sugiura K, Sugiura M. 2016. Immune Checkpoint Blockade Therapy: Merits and Demerits. J Clin Exp Dermatol Res. 7:372

Tagged under: ATPase Assay, HSP90 Inhibitors, Transcreener ADP Kinase Assay

What you can read next

Battling Lysosomal Storage Diseases with ERT and SRT
BellBrook Labs Awarded NIH Funding for Collaboration with University of Utah to Develop Biosensors for Epigenetic Drug Discovery
Residence Time Guide
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARG in Human Immunity

    Discovering the Emerging Importance of PARG in Immunity

    Poly (ADP-ribose) glycohydrolase (PARG), along ...
  • Helicases Used in Innate Immunity

    Helicases as Powerful Tools in Innate Immunity

    Helicases are among the largest and most highly...
  • Info book on cancer and RAFK1's relation

    RAF1 & Immunity: A Future Model For Cancer Research?

    RAF1, also known as c-Raf, is a member of the R...
  • OAS1 The Cost of Host Defense

    OAS1: The Cost of Host Defense

    OAS1 (Oligoadenylate synthetase 1) is induced b...
  • Scientist Studying DDX41

    DDX41 as a Sensor, Suppressor, and Modulator

    DDX41 [DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 4...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP